Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive In Vivo Models for Oncology.
Behrens D, Rolff J, Hoffmann J. Behrens D, et al. Handb Exp Pharmacol. 2016;232:203-21. doi: 10.1007/164_2015_29. Handb Exp Pharmacol. 2016. PMID: 26489829 Review.
Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity Testing.
Behrens D, Pfohl U, Conrad T, Becker M, Brzezicha B, Büttner B, Wagner S, Hallas C, Lawlor R, Khazak V, Linnebacher M, Wartmann T, Fichtner I, Hoffmann J, Dahlmann M, Walther W. Behrens D, et al. Cancers (Basel). 2023 Dec 8;15(24):5753. doi: 10.3390/cancers15245753. Cancers (Basel). 2023. PMID: 38136299 Free PMC article.
Pancreatic cancer models for translational research.
Behrens D, Walther W, Fichtner I. Behrens D, et al. Pharmacol Ther. 2017 May;173:146-158. doi: 10.1016/j.pharmthera.2017.02.013. Epub 2017 Feb 4. Pharmacol Ther. 2017. PMID: 28174092 Review. No abstract available.
TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer.
Zhao B, Dierichs L, Gu JN, Trajkovic-Arsic M, Axel Hilger R, Savvatakis K, Vega-Rubin-de-Celis S, Liffers ST, Peña-Llopis S, Behrens D, Hahn S, Siveke JT, Lueong SS. Zhao B, et al. Among authors: behrens d. Cell Death Discov. 2020 Mar 11;6:12. doi: 10.1038/s41420-020-0246-7. eCollection 2020. Cell Death Discov. 2020. PMID: 32194992 Free PMC article.
Animal models for personalized treatment options.
Fichtner I, Klinghammer K, Behrens D, Flechsig S, Rolff J, Becker M, Wulf-Goldenberg A, Stecklum M, Rivera M, Brzezicha B, Jandrig B, Hoffmann J. Fichtner I, et al. Among authors: behrens d. Int J Clin Pharmacol Ther. 2017 Aug;55(8):698-700. doi: 10.5414/CPXCES15EA09. Int J Clin Pharmacol Ther. 2017. PMID: 28696202 No abstract available.
Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation.
Godfrey LK, Forster J, Liffers ST, Schröder C, Köster J, Henschel L, Ludwig KU, Lähnemann D, Trajkovic-Arsic M, Behrens D, Scarpa A, Lawlor RT, Witzke KE, Sitek B, Johnsen SA, Rahmann S, Horsthemke B, Zeschnigk M, Siveke JT. Godfrey LK, et al. Among authors: behrens d. Clin Epigenetics. 2024 Jan 16;16(1):13. doi: 10.1186/s13148-024-01623-z. Clin Epigenetics. 2024. PMID: 38229153 Free PMC article.
115 results